Pediatric Cancer News An analysis of previously approved novel anticancer agents estimates that more than 78% would have met the RACE for Children Act criteria for pediatric testing.
The authors of this article emphasized the importance of actively involving a diverse group of interdisciplinary team members in the psychosocial care of these patients.
Medical and ethical considerations are discussed, including in cases of conflict between parent, child.
Risk for coronary artery disease significantly decreased for survivors with diagnosis in 80s, 90s versus 70s.
At 3 days before a bloodstream infection, mcfDNA sequencing correctly predicted 12 of the 16 observed episodes.
Of all types of fertility treatment examined, the only one that significantly increased the risk of cancer in children was frozen embryo transfer.
Greatest gaps in life expectancy seen for those receiving radiotherapy, alone or combined with chemo.
The increased prevalence may be real, or it could be the result of the detection of more harmless tumors through increased screening efforts.
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall.
Study sought to determine if response to upfront treatment in children and adolescents with Hodgkin lymphoma is influenced by race/ethnicity.
The addition of bevacizumab to temozolomide-based chemotherapy was also associated with higher rates of grade 3 or higher thrombocytopenia and anemia.
As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap.
Exposure to ≥250 mg/m² doxorubicin-equivalent anthracycline chemo tied to risk for CVD, heart failure.
Survivors of childhood cancers who were treated with anthracyclines are at increased risk for developing breast cancer.
Working group reviewed bone complications to form recommendations for management of bone health.
Burden of childhood cancers disproportionately affects populations in resource-limited settings.
The increased prevalence may be real, or it could be the result of the detection of more harmless tumors through increased screening efforts.
A primary outcome measure for phase 1 of the trial is determining the safety of oral LOXO-292.
After phase 1, the study will expand in a second phase to test the efficacy of these drugs at the determine dosage.
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
Load More
